Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05076942 · ClinicalTrials.gov registry record · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
A Phase 2 study of Vulvar Cancer and Sentinel Lymph Node, sponsored by University Medical Center Groningen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
- 20
- Study locations
NCT05076942: Recruiting Phase 2 study of Vulvar Cancer and Sentinel Lymph Node, sponsored by University Medical Center Groningen.
NCT05076942 is a Phase 2 study of Vulvar Cancer and Sentinel Lymph Node that is actively recruiting participants, run by University Medical Center Groningen. The registered enrollment target is 157 participants, below the 444-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05076942, a Phase 2 study of Vulvar Cancer and Sentinel Lymph Node, is actively recruiting participants, sponsored by University Medical Center Groningen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
- 20
- Study locations
Study Summary
Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Primary Outcome
Groin recurrence in the groin with SN metastasis treated with chemoradiation
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION Radiotherapy combined with cisplatin
Study Locations (20)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Michigan
- Spectrum Health at Butterworth Campus - Grand Rapids
- Munson Medical Center - Traverse City
North Carolina
- Duke University Medical Center - Durham
- Duke Women's Cancer Care Raleigh - Raleigh
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
- ProMedica Flower Hospital - Sylvania
California
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
Florida
- Mount Sinai Medical Center - Miami Beach
Massachusetts
- Baystate Medical Center - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
What NCT05076942 shows while recruiting
NCT05076942 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, below the 444-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Vulvar Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cisplatin is the first listed.
NCT05076942 names 20 study sites across 12 states, led by New York, New Jersey, Michigan.
Frequently Asked Questions
What is clinical trial NCT05076942 about?
NCT05076942 is a clinical study titled "Groningen International Study on Sentinel Nodes in Vulvar Cancer-III". Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
What is the current status of trial NCT05076942?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2021-01-01. Estimated completion is 2029-01-01.
What conditions does trial NCT05076942 study?
This clinical trial studies the following conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases.
What interventions are being tested in trial NCT05076942?
The interventions under investigation include: Cisplatin (DRUG), Radiotherapy combined with cisplatin (RADIATION).
Who is sponsoring clinical trial NCT05076942?
This trial is sponsored by University Medical Center Groningen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05076942 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvar Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05076942's enrollment target sits among peer trials
157 4th of 17 higher than 14 of 17 other Vulvar Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vulvar Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
ACTIVE NOT RECRUITING · Phase 2
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- NCT07266441 · 157 participants · Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI